Synapse - Find an Expert

33620 Results

Aberrant cathepsin S induces a supportive immune microenvironment in follicular lymphoma

Meeting Abstract

Hildebrand, J. A.; Bararia, D.; Stolz, S.; Haebe, S.; Alig, S.; Bartoschek, M.; Boesl, M.; Pastore, A.; Gaitzsch, E.; Heide, M.; more...
Blood (2019)

Fulltext@MSK | Save

Inducible phase separation of GSK3α as a mechanism for asparaginase resistance in acute leukemias

Meeting Abstract

Hinze, L.; Schreek, S.; Zeug, A.; Ponimaskin, E.; Labrosse, R.; Degar, J.; Chiosis, G.; Pai, S. Y.; Stevenson, K. E.; Neuberg, D. S.; more...
Blood (2019)

Fulltext@MSK | Save

RIG-I activation is critical for responsiveness to checkpoint blockade

Meeting Abstract

Heidegger, S.; Wintges, A.; Stritzke, F.; Steiger, K.; Koenig, P. A.; Engleitner, T.; Fischer, J. C.; Makarov, V.; Winter, C.; Rad, R.; more...
Blood (2019)

Fulltext@MSK | Save

Patient-reported outcome results from the US Life after Stopping TKIs (LAST) study in patients with chronic myeloid leukemia

Meeting Abstract

Flynn, K. E.; Weinfurt, K. P.; Lin, L.; Radich, J. P.; Schiffer, C. A.; Mauro, M. J.; Ibarz, J. P.; Moore, J. O.; Larson, R. A.; Oehler, V. G.; more...
Blood (2019)

Fulltext@MSK | Save

Maintenance decitabine (DAC) improves disease-free (DFS) and overall survival (OS) after intensive therapy for acute myeloid leukemia (AML) in older adults, particularly in FLT3-ITD-negative patients: ECOG-ACRIN (E-A) E2906 randomized study

Meeting Abstract

Foran, J. M.; Sun, Z.; Claxton, D. F.; Lazarus, H. M.; Arber, D. A.; Rowe, J. M.; Paietta, E.; Racevskis, J.; Altman, J. K.; Luger, S. M.; more...
Blood (2019)

Fulltext@MSK | Save

Enasidenib plus azacitidine significantly improves complete remission and overall response compared with azacitidine alone in patients with newly diagnosed acute myeloid leukemia (AML) with isocitrate dehydrogenase 2 (IDH2) mutations: Interim phase II results from an ongoing, randomized study

Meeting Abstract

DiNardo, C. D.; Schuh, A. C.; Stein, E. M.; Montesinos Fernandez, P.; Wei, A.; De Botton, S.; Zeidan, A. M.; Fathi, A. T.; Quek, L.; Kantarjian, H. M.; more...
Blood (2019)

Fulltext@MSK | Save

Primary results from the phase 3 TOURMALINE-AL1 trial of ixazomib-dexamethasone versus physician's choice of therapy in patients (Pts) with relapsed/refractory primary systemic AL amyloidosis (RRAL)